<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385788</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0015</org_study_id>
    <secondary_id>NCI-2012-01376</secondary_id>
    <nct_id>NCT00385788</nct_id>
  </id_info>
  <brief_title>Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation Followed By Adoptive Immunotherapy for Patients With Relapsed and Refractory Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if fludarabine, melphalan and
      gemcitabine followed by transplantation of stem cells (blood-forming cells) as well as immune
      cells (lymphocytes), collected from a matched related (i.e. a sibling) or unrelated donor, or
      a mismatched related donor, can help to control Hodgkin's disease. The safety of the
      treatment will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central Venous Catheter:

      If you choose to take part in this study, the chemotherapy, some of the other drugs in this
      study, and the stem cell transplant and immune cells will be given by vein through your
      central venous catheter (CVC). A CVC is a sterile flexible tube and needle that will be
      placed into a large vein while you are under local anesthesia. Blood samples will also be
      drawn through your CVC. The CVC will remain in your body during treatment. Your doctor will
      explain this procedure to you in more detail, and you will be required to sign a separate
      consent form.

      Study Drug Administration:

      The days before you receive your stem cells are called minus days, such as Day -2, Day -1.
      The day you receive the stem cells is called Day 0. The days after you receive the stem cells
      are called plus days, such as Day +1, Day +2.

      On Day -7, you will receive gemcitabine by vein over about 40-180 minutes.

      On Day -6, you will be admitted to the hospital and given fluids by vein to hydrate you.

      On Days -5 and -4, you will receive fludarabine by vein over about 30 minutes.

      On Days -4 and -3, you will receive thymoglobulin, if you are receiving a transplant from a
      matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative,
      but not a full match), you will also receive antithymocyte globulin (ATG)

      On Days -3 and -2, you will receive fludarabine by vein over about 30 minutes and melphalan
      over about 30 minutes.

      On Day -1, you will &quot;rest&quot; (not receive chemotherapy).

      On Day 0, you will receive the donor's stem cells and immune cells by vein. The infusion will
      last anywhere from about 30 minutes to several hours. You may be given other standard drugs
      to help lower the risk of side effects. You may ask the study staff for more information
      about how the drugs are given and their risks. All participants are expected to need blood
      transfusions as part of this treatment.

      Beginning on Day -2, tacrolimus will be given by vein over 24 hours to help lower the risk of
      graft-versus-host disease (GVHD). This will be changed to pills once you can tolerate
      swallowing pills. If no active cancer is detected and there is no GVHD, you will then swallow
      1 or more tacrolimus pills a day for only about 3-4 months, instead of the usual period of 6
      months. This is done to boost the donor immune system against the cancer.

      Starting 1 week after the transplant (Day +7), you will receive filgrastim (G-CSF) as an
      injection under the skin 1 time each day until your blood cell levels return to normal.
      Filgrastim is designed to make white blood cells grow, which may help to fight infections.

      On Days +1, +3, +6, and +11, you will receive methotrexate by vein to decrease the risk of
      GVHD.

      If you have persistent but stable (not &quot;growing&quot;) disease after transplant, you will have
      your immunosuppressive medications (tacrolimus, corticosteroids) stopped even before 4
      months. If there is no response, you will receive an infusion of additional cells from your
      donor.

      Study Visits:

      About 30 days before receiving the stem cells, you will have computed tomography (CT) and/or
      positron emission tomography (PET) scans to check the status of the disease.

      About every day until discharge, and then at least weekly:

        -  You will have a physical exam.

        -  Blood (about 4 tablespoons) will be drawn for routine tests.

      Follow-Up Visits:

      About 100 days after the transplant:

        -  You will have a physical exam.

        -  Blood (about 4 tablespoons) will be drawn for routine tests. Part of the blood sample
           may be used for chimerism analysis (determination of donor or recipient cells), if
           needed.

        -  At any point that your doctor thinks they are needed, you will have a bone marrow
           aspiration, chest x-rays, and CT and/or PET scans to check the status of the disease. To
           collect a bone marrow aspirate, an area of the hip or other site is numbed with
           anesthetic, and a small amount of bone marrow is withdrawn through a large needle.

      About 6 months, 1 year, then annually after the transplant:

        -  You will have a physical exam.

        -  Blood (about 4 tablespoons) will be drawn for routine tests. Part of the blood sample
           may be used for chimerism analysis (determination of donor or recipient cells), if
           needed. Part of the blood will be used to check your thyroid function once a year.

        -  At any point that your doctor thinks they are needed, you will have a bone marrow
           aspiration, chest x-rays, and CT and/or PET scans to check the status of the disease.

        -  You may have lung function tests, if your doctor thinks it is needed.

        -  About 6 months after the transplant, you may have a biopsy, if your doctor thinks it is
           needed.

        -  About once a year, you will have an eye exam.

      The above tests/procedures may be repeated more often, if you doctor thinks it is needed.

      The study staff will also stay in contact with your local doctor to find out if the disease
      comes back and to check how you are doing.

      Length of Treatment:

      You will be on study for about 3 years. After 1 year, there is no study specific testing you
      will be required to complete. Your transplant doctor will perform routine standard of care
      follow-up that all patients receiving allogeneic stem cell transplantation receive.

      You may be removed from the study early if the doctor thinks it is in your best interest, if
      the disease gets worse or comes back, if intolerable side effects occur, if you have graft
      failure (the transplanted cells do not grow), or if you are unable to follow study
      directions.

      If for any reason you want to leave the study early, you must talk to the study doctor. It
      may be life-threatening to leave the study after you have started to receive the study drugs
      but before you receive the stem cell transplant because your blood cell counts will be
      dangerously low.

      This is an investigational study. All of the drugs used in this study are FDA-approved and
      commercially available. Up to 70 patients will take part in this study. All will be enrolled
      at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant Related Mortality Rate</measure>
    <time_frame>Transplant to 100 days post transplant</time_frame>
    <description>Transplant-related mortality defined as death from any cause in the first 100 days post-transplant in patients without active disease.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Hodgkin's Disease</condition>
  <arm_group>
    <arm_group_label>Gemcitabine + Fludarabine + Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes for one day; Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludarabine + Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>800 mg/m^2 IV over 30 minutes on Day -7 (1 day)</description>
    <arm_group_label>Gemcitabine + Fludarabine + Melphalan</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>Gemcitabine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>33 mg/m^2 IV over 30 minutes Day -5 to Day -2 (4 days)</description>
    <arm_group_label>Gemcitabine + Fludarabine + Melphalan</arm_group_label>
    <arm_group_label>Fludarabine + Melphalan</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>70 mg/m^2 IV over 30 minutes on Day -3 to Day -2 (2 days)</description>
    <arm_group_label>Gemcitabine + Fludarabine + Melphalan</arm_group_label>
    <arm_group_label>Fludarabine + Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithymocyte Globulin</intervention_name>
    <description>2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.
If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant.</description>
    <arm_group_label>Gemcitabine + Fludarabine + Melphalan</arm_group_label>
    <arm_group_label>Fludarabine + Melphalan</arm_group_label>
    <other_name>ATG</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Stem Cell Infusion</intervention_name>
    <description>Infusion of stem cells on Day 0.</description>
    <arm_group_label>Gemcitabine + Fludarabine + Melphalan</arm_group_label>
    <arm_group_label>Fludarabine + Melphalan</arm_group_label>
    <other_name>AST</other_name>
    <other_name>Stem Cell Transplantation</other_name>
    <other_name>SCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.</description>
    <arm_group_label>Gemcitabine + Fludarabine + Melphalan</arm_group_label>
    <arm_group_label>Fludarabine + Melphalan</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim (G-CSF)</intervention_name>
    <description>Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.</description>
    <arm_group_label>Gemcitabine + Fludarabine + Melphalan</arm_group_label>
    <arm_group_label>Fludarabine + Melphalan</arm_group_label>
    <other_name>Granul</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.</description>
    <arm_group_label>Gemcitabine + Fludarabine + Melphalan</arm_group_label>
    <arm_group_label>Fludarabine + Melphalan</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients &lt; 65 years of age with histologically confirmed refractory or relapsed
             Hodgkin's disease (including patients who fail or relapse after autologous SCT). This
             upper age limit will apply to transplants from both matched related and unrelated
             donors.

          2. Patients should have any of the following disease status: a. responsive or stable
             disease on salvage chemotherapy or radiation therapy. b. untreated, smoldering (i.e.
             not rapidly progressive) relapses.

          3. Patients must have a serum bilirubin equal to or &lt;/=2.0 mg/dl (isolated
             hyperbilirubinemia related to Gilbert's disease allowed), serum transaminase (ALT)
             equal to or &lt;/= 3 times the upper limit of the normal range, serum creatinine &lt;2.0
             mg/dl (provided they also have a glomerular filtration rate of at least 55 ml/min), no
             symptomatic cardiac or pulmonary disease and a performance status equal to or &lt;/=2.
             Left ventricular ejection fraction &gt;/= 40%, forced expiratory volume at one second
             (FEV1), forced vital capacity (FVC) and corrected diffusing capacity of lung for
             carbon monoxide (DLCO) &gt;/= 50% predicted.

          4. Patients must have an HLA-compatible related or unrelated donor (one-antigen
             mismatched related donors are acceptable) willing to donate marrow or
             rhG-CSF-mobilized peripheral blood stem cells. In the event of transplants from
             matched unrelated donors, a high-resolution allele match for HLA-A, -B, -C, -DRB1 (&quot;8
             of 8 match&quot;) is required.

          5. Women of childbearing potential must have a negative serum pregnancy test within two
             weeks of study entry and should be advised to avoid becoming pregnant. Men should be
             advised to not father a child while on treatment. Both women of childbearing potential
             and men must agree to practice effective methods of contraception.

          6. Patients must be capable and willing to sign informed consent.

        Exclusion Criteria:

          1. Patients with documented disease progression on salvage chemotherapy.

          2. Nursing or pregnant females. Should a woman become pregnant or suspect she is pregnant
             while participating in the study, she should inform her treating physician
             immediately.

          3. Severe concomitant medical or psychiatric illness.

          4. Uncontrolled arrhythmia or symptomatic cardiac or pulmonary disease.

          5. Chronic active hepatitis or cirrhosis.

          6. Active or uncontrolled infection.

          7. Radiation therapy involving chest (axilla excluded), mediastinum, or abdomen (i.e.,
             small or large bowel) completed within 10 weeks of transplant admission. Radiation
             therapy shortly before the start of the preparative regimen is allowed.

          8. Prior or concurrent malignancies (including myelodysplasia) except resected basal cell
             carcinoma or treated carcinoma in-situ. Cancer treated with curative intent &lt; 5 years
             previously will not be allowed unless approved by the Protocol Chair. Cancer treated
             with curative intent &gt; 5 years previously will be allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Anderlini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <results_first_submitted>August 22, 2017</results_first_submitted>
  <results_first_submitted_qc>April 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2018</results_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin's Disease</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>Antithymocyte Globulin</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Gemzar</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <keyword>AST</keyword>
  <keyword>SCT</keyword>
  <keyword>ATG</keyword>
  <keyword>Thymoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: July 14, 2005 to June 26, 2015. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>First cohort (n=12) was treated before addition of Gemcitabine in the preparative regimen.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fludarabine + Melphalan</title>
          <description>Fludarabine 33 mg/m^2 IV Day -5 to Day -2 (4 days); Melphalan 70 mg/m^2 IV over 30 minutes Day -3 to Day -2 (2 days). Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation Day 0. Tacrolimus 0.03 mg/kg IV Day -2 over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.</description>
        </group>
        <group group_id="P2">
          <title>Gemcitabine + Fludarabine + Melphalan</title>
          <description>Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes Day -7; Fludarabine 33 mg/m^2 IV Day -5 to Day -2 (4 days); Melphalan 70 mg/m^2 IV over 30 minutes Day -3 to Day -2 (2 days). Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation Day 0. Tacrolimus 0.03 mg/kg IV Day -2 over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fludarabine + Melphalan</title>
          <description>Fludarabine 33 mg/m^2 IV Day -5 to Day -2 (4 days); Melphalan 70 mg/m^2 IV over 30 minutes Day -3 to Day -2 (2 days). Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation Day 0. Tacrolimus 0.03 mg/kg IV Day -2 over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) subcutaneously once daily + Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.</description>
        </group>
        <group group_id="B2">
          <title>Gemcitabine + Fludarabine + Melphalan</title>
          <description>Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes Day -7; Fludarabine 33 mg/m^2 IV Day -5 to Day -2 (4 days); Melphalan 70 mg/m^2 IV over 30 minutes Day -3 to Day -2 (2 days). Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation Day 0. Tacrolimus 0.03 mg/kg IV Day -2 over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) subcutaneously once daily + Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" lower_limit="21" upper_limit="58"/>
                    <measurement group_id="B2" value="31" lower_limit="20" upper_limit="63"/>
                    <measurement group_id="B3" value="30" lower_limit="20" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Transplant Related Mortality Rate</title>
        <description>Transplant-related mortality defined as death from any cause in the first 100 days post-transplant in patients without active disease.</description>
        <time_frame>Transplant to 100 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine + Melphalan</title>
            <description>Fludarabine 33 mg/m^2 IV Day -5 to Day -2 (4 days); Melphalan 70 mg/m^2 IV over 30 minutes Day -3 to Day -2 (2 days). Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation Day 0. Tacrolimus 0.03 mg/kg IV Day -2 over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) subcutaneously once daily + Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine + Fludarabine + Melphalan</title>
            <description>Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes Day -7; Fludarabine 33 mg/m^2 IV Day -5 to Day -2 (4 days); Melphalan 70 mg/m^2 IV over 30 minutes Day -3 to Day -2 (2 days). Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation Day 0. Tacrolimus 0.03 mg/kg IV Day -2 over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) subcutaneously once daily + Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant Related Mortality Rate</title>
          <description>Transplant-related mortality defined as death from any cause in the first 100 days post-transplant in patients without active disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected through post transplant with routine standard of care follow-up for patients receiving allogeneic stem cell transplantation, up to 100 days post-op.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fludarabine + Melphalan</title>
          <description>Fludarabine 33 mg/m^2 IV Day -5 to Day -2 (4 days); Melphalan 70 mg/m^2 IV over 30 minutes Day -3 to Day -2 (2 days). Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation Day 0. Tacrolimus 0.03 mg/kg IV Day -2 over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) subcutaneously once daily + Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.</description>
        </group>
        <group group_id="E2">
          <title>Gemcitabine + Fludarabine + Melphalan</title>
          <description>Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes Day -7; Fludarabine 33 mg/m^2 IV Day -5 to Day -2 (4 days); Melphalan 70 mg/m^2 IV over 30 minutes Day -3 to Day -2 (2 days). Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation Day 0. Tacrolimus 0.03 mg/kg IV Day -2 over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) subcutaneously once daily + Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestional (GI) Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Systemic Inflammatory Response Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure/Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Primary Graft Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure/Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure/Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Respiratory Distress due to Infusion Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension (HTN)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pneumatosis Coli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="31" subjects_affected="26" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="66" subjects_affected="40" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>BK Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Secondary Graft Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin</sub_title>
                <description>(hyperbilirubinemia)</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E2" events="40" subjects_affected="24" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Neurologic Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Operations Team, Office of VP Clinical Research</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-7734</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

